Concepedia

Ryan Bjordahl

RB

Statistics

Publications

21

Citations

1.5K

H-Index

16

Active since

2007

Affiliations

Fate Therapeutics (United States)(Current)

University of Minnesota

Karolinska Institutet

Max Delbrück Center

University of California San Diego

Ryan Bjordahl is an author at Fate Therapeutics (United States) specializing in immunology, life sciences, and cancer immunology.

ORCID

Publications per year

2007–2023

21

Publications

21

Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity

Zhu Huang, Robert Blum, Ryan Bjordahl et al. · Blood · 2019 · 275 citations · Full text

, , +17

iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti–PD-1 therapy

Frank Cichocki, Ryan Bjordahl, Svetlana Gaidarova et al. · Science Translational Medicine · 2020 · 239 citations · Full text

, , +17

Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy

Karrune Woan, Hansol Kim, Ryan Bjordahl et al. · Cell stem cell · 2021 · 154 citations · Full text

, , +16

GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity

Frank Cichocki, Bahram Valamehr, Ryan Bjordahl et al. · Cancer Research · 2017 · 140 citations

, , +17

CD160 Activation by Herpesvirus Entry Mediator Augments Inflammatory Cytokine Production and Cytolytic Function by NK Cells

John R. Šedý, Ryan Bjordahl, Vasileios Bekiaris et al. · The Journal of Immunology · 2013 · 104 citations · Full text

, , +13

1–5 of 21